Preoperative serum MMP-9 immunoreactive protein is a prognostic indicator for relapse-free survival in breast carcinoma
- 1 January 2005
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 217 (2) , 237-242
- https://doi.org/10.1016/j.canlet.2004.06.056
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinomaBritish Journal of Cancer, 2003
- Increased plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in lung and breast cancer are altered during chest radiotherapyInternational Journal of Radiation Oncology*Biology*Physics, 2003
- Matrix Metalloproteinase-2 (MMP-2) in T1–2N0 breast carcinomaBreast Cancer Research and Treatment, 2003
- Expression of proteinases and inhibitors in human breast cancer progression and survivalMolecular Pathology, 2002
- Proteolysis in human breast cancerMolecular Pathology, 2000
- MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinomaBreast Cancer Research and Treatment, 1999
- Proteolysis in human breast and colorectal cancerBritish Journal of Cancer, 1999
- Matrix metalloproteinase-2 immunoreactive proteinCancer, 1998
- Production of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Human Breast CarcinomasJapanese Journal of Cancer Research, 1996
- Cancer metastasis and angiogenesis: An imbalance of positive and negative regulationCell, 1991